| 1. |
- Alsterholm, Mikael, 1977, et al.
(författare)
-
Establishment and utility of SwedAD : a nationwide Swedish registry for patients with atopic dermatitis receiving systemic pharmacotherapy
- 2023
-
Ingår i: Acta Dermato-Venereologica. - : Medical Journals Sweden AB. - 0001-5555 .- 1651-2057. ; 103
-
Tidskriftsartikel (refereegranskat)abstract
- SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis.
|
|
| 2. |
- Moberg, Christina, et al.
(författare)
-
De unga gör helt rätt när de stämmer staten
- 2022
-
Ingår i: Aftonbladet. - 1103-9000.
-
Tidskriftsartikel (populärvet., debatt m.m.)abstract
- 1 620 forskare och lärare i forskarvärlden: Vi ställer oss bakom Auroras klimatkrav
|
|
| 3. |
|
|
| 4. |
- Birnbaum, Daniel, et al.
(författare)
-
Thirteen questions about the object to Graham Harman
- 2020
-
Ingår i: Artful objects : Graham Harman on art and the business of speculative realism. - Berlin ; Stockholm : Sternberg Press ; Stockholm School of Economics. - 9783956795244 ; , s. 43-72
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 5. |
- Bjärstig, Therese, 1978-, et al.
(författare)
-
(How) Can adaptive moose management contribute to sustainable rural development?
- 2013
-
Ingår i: Welcome to the Anthropocene! The Nordic Environmental Social Science Conference, 11‐13 June 2013. - : University of Copenhagen. ; , s. 154-154
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- The concept of adaptive management (AM) is widely advocated as an alternative to traditional top-down management of natural resources around the world. In Sweden, however, AM has only recently been introduced to manage moose. Based on the analytical framework, developed by Pieter Glasbergen (2011), we study the AM of moose as a case of a partnership arrangement within the field of wildlife governance. We put particular attention on how adaptive moose management enables sustainable rural development, since hunting is considered to be an important source of recreation and livelihood in Swedish rural areas. We identify a number of challenges associated to the involved stakeholders’ abilities, willingness and understanding to implement the induced management system. We also emphasis the interactions between the different stakeholders on both vertical and horizontal levels, as well as the tradeoffs the new ecosystem based adaptive local management system generates for rural and urban areas.
|
|
| 6. |
- Bjärstig, Therese, 1978-, et al.
(författare)
-
Partnerships implementing ecosystem-based moose management in Sweden
- 2014
-
Ingår i: International Journal of Biodiversity Science, Ecosystem Services & Management. - : Taylor & Francis. - 2151-3732 .- 2151-3740. ; 10:3, s. 228-239
-
Tidskriftsartikel (refereegranskat)abstract
- Sweden is undergoing an extensive transformation from single species management towards ecosystem-based management. This study analyses the implementation of the new moose management system, focusing on the newly formed partnerships at ecosystem level (the moose management areas) and their potential to ease conflicts between participants and develop into sustainable collaborations that enable ecosystem-based management. Empirical evidence was obtained from semi-structured interviews with involved actors (hunters, landowners, wildlife managers and forest consultants) in five Swedish counties. Several challenges, based on the participants’ abilities, willingness and understanding needed to implement the new management system, were identified. Lack of funding, unclear roles and responsibilities appear to be the most serious issues. If these are not properly solved, then they have the potential to hamper and aggravate the implementation of the new management system, that is, the ecosystem-based management, as well as the partnership arrangement.
|
|
| 7. |
|
|
| 8. |
- Bragina, Olga, et al.
(författare)
-
Phase I study of 99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Radionuclide molecular imaging of human epidermal growth factor (HER2) expression may be helpful to stratify breast and gastroesophageal cancer patients for HER2-targeting therapies. ADAPTs (albumin-binding domain derived affinity proteins) are a new type of small (46-59 amino acids) proteins useful as probes for molecular imaging. The aim of this first in-human study was to evaluate biodistribution, dosimetry, and safety of HER2-specific 99mTc-ADAPT6.METHODS. Twenty-two patients with HER2-positive (n=11) or HER2-negative (n=11) primary breast cancer were intravenously injected with 385125 MBq. The injected amount of protein was either 500 μg (n=11) or 1000 μg (n=11). Planar scintigraphy followed by SPECT imaging was performed after 2, 4, 6 and 24 h. An additional cohort received a dose of 250 μg, and the planar scintigraphy followed by SPECT imaging was performed after 2 h only.RESULTS. Injection of 99mTc-ADAPT6 was well tolerated for all doses evaluated in the study, and was not associated with any adverse effects. 99mTc-ADAPT6 cleared rapidly from the blood and the majority of tissues. The normal organs with the highest accumulation were kidney, liver and lung. The effective doses were determined to 0.0090.002 and 0.0100.003 mSv/MBq when injecting protein amounts of 500 and 1000 μg, respectively. Injection of 500 μg resulted in excellent discrimination between HER2-positive and HER2-negative tumors already 2 h after injection (tumor-to-contralateral breast ratio was 3719 vs 52, p < 0.01). The tumor-to-contralateral breast ratios for HER2-positive tumors were significantly (p < 0.5) higher for the injected mass of 500 μg than for both 250 and 1000 μg. In one patient, the imaging using 99mTc-ADAPT6 revealed three bone metastases, which were not found at the time of diagnosis by CT or 99mTcpyrophosphate bone scan. MRI imaging confirmed this finding.CONCLUSION. Injections of 99mTc-ADAPT6 are safe and associated with low absorbed and effective doses. A protein dose of 500 μg is preferable for discrimination between tumors with high and low expression of HER2. 99mTc-ADAPT6 is a promising imaging probe for the stratification of patients for HER2-targeting therapy.
|
|
| 9. |
- Bragina, Olga, et al.
(författare)
-
Phase I study of 99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer
- 2021
-
Ingår i: Journal of Nuclear Medicine. - : Society of Nuclear Medicine. - 0161-5505 .- 1535-5667 .- 2159-662X. ; 62:4, s. 493-499
-
Tidskriftsartikel (refereegranskat)abstract
- Radionuclide molecular imaging of human epidermal growth factor (HER2) expression may be helpful to stratify breast and gastroesophageal cancer patients for HER2-targeting therapies. ADAPTs (albumin-binding domain derived affinity proteins) are a new type of small (46-59 amino acids) proteins useful as probes for molecular imaging. The aim of this first-in-human study was to evaluate biodistribution, dosimetry, and safety of the HER2-specific 99mTc-ADAPT6.METHODS: Twenty-nine patients with primary breast cancerwere included. In 22 patients with HER2-positive (n = 11) or HER2-negative (n = 11) histopathology an intravenous injection with 385±125 MBq 99mTc-ADAPT6 was performed, randomized to an injected protein mass of either 500 µg (n = 11) or 1000 µg (n = 11). Planar scintigraphy followed by SPECT imaging was performed after 2, 4, 6 and 24 h. An additional cohort (n = 7) was injected with 165±29 MBq (injected protein mass 250 µg) and imaging was performed after 2 h only.RESULTS: Injections of 99mTc-ADAPT6 at all injected mass levels were well tolerated and not associated with adverse effects. 99mTc-ADAPT6 cleared rapidly from blood and most other tissues. The normal organs with the highest accumulation were kidney, liver and lung. Effective doses were 0.009±0.002 and 0.010±0.003 mSv/MBq for injected protein masses of 500 and 1000 µg, respectively. Injection of 500 µg resulted in excellent discrimination between HER2-positive and HER2-negative tumors already 2 h after injection (tumor-to-contralateral breast ratio was 37±19 vs 5±2, p<0.01). The tumor-to-contralateral breast ratios for HER2-positive tumors were significantly (p<0.05) higher for injected mass of 500 µg than for both 250 and 1000 µg.CONCLUSION: Injections of 99mTc-ADAPT6 are safe and associated with low absorbed and effective doses. Protein dose of 500 µg is preferable for discrimination between tumors with high and low expression of HER2. Further studies are justified to evaluate if 99mTc-ADAPT6 can be used as an imaging probe for stratification of patients for HER2-targeting therapy in the areas where PET imaging is not readily available.
|
|
| 10. |
- de Wit Sandström, Ida, et al.
(författare)
-
Bortom klädkoder : En introduktion till estetiskt arbete
- 2021
-
Ingår i: Modevetenskap : Perspektiv på mode, stil och estetik - Perspektiv på mode, stil och estetik. - 9789198548563 ; , s. 292-309
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
